We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
News

Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform

Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
News

Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ChemAxon has announced that Boehringer Ingelheim has chosen its chemistry software platform for multiple applications across research and development, supporting in-house activities and work with external collaboration partners.

ChemAxon technology will be used to store, search, calculate, and visualize chemical entities, properties and reactions, helping to streamline the progression from drug discovery to clinical candidate.

ChemAxon was chosen after an extensive evaluation process that built on dimensions such as ROI, performance, robustness, scalability and future development roadmap.

ChemAxon sets the standard in chemically-intelligent software for pharmaceutical R&D.

With a client list that includes all of the top 15 global pharma companies, the company continues to experience significant growth year on year.

Commenting on the agreement, Alex Drijver, CEO of ChemAxon said, “The adoption of ChemAxon technology by Boehringer Ingelheim further underlines our position as the platform of choice for R&D organizations planning their next-generation systems.”

Advertisement